dt 5461 has been researched along with Experimental Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akimoto, T; Jimbo, T; Joto, N; Kita, Y; Kumazawa, E; Tohgo, A | 1 |
| Kumazawa, E; Kusama, T; Osada, Y; Soga, T; Tohgo, A | 1 |
2 other study(ies) available for dt 5461 and Experimental Neoplasms
| Article | Year |
|---|---|
Intratumoral production of tumor necrosis factor augmented by endogenous interferons results in potent antitumor effects of DT-5461, a synthetic lipid A analog.
Topics: Animals; Antineoplastic Agents; Disaccharides; Drug Administration Schedule; Interferons; Lipid A; Male; Mice; Mice, Inbred BALB C; Neoplasms, Experimental; RNA, Messenger; Tumor Necrosis Factor-alpha | 1995 |
Significant antitumor effect of a synthetic lipid A analogue, DT-5461, on murine syngeneic tumor models.
Topics: Animals; Antineoplastic Agents; Ascites; Bone Marrow; Disaccharides; Lipid A; Male; Mice; Mice, Inbred Strains; Neoplasms, Experimental; Picibanil; Tumor Cells, Cultured | 1992 |